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Looking Beyond Hypertension*Joost Daemen, MD, PHDSEE PAGE 972S ince 2006, endovascular renal sympatheticdenervation has been studied as a potentialtherapy for patients with treatment-resistant
hypertension. In the years that followed, numerous
studies were published reporting on the remarkable
blood pressure–lowering effects of renal sympa-
thetic denervation, generating almost boundless
enthusiasm. This sentiment was strengthened by
multiple reports showing that the technology could
be of tremendous beneﬁt in treating metabolic syn-
drome, renal failure, obstructive sleep apnea, heart
failure, atrial ﬁbrillation, and even polycystic ovary
syndrome, suggesting potential pleiotropic effects
of the therapy designed to reduce sympathetic
nerve activity. Since 2014, however, the results of
the sham-controlled Symplicity HTN-3 (Renal
Denervation in Patients With Uncontrolled Hyper-
tension) trial overshadowed the initial over-
whelming enthusiasm about renal denervation
when the trial ﬁndings turned out to be negative,
and it was concluded that “renal denervation does
not reduce blood pressure as compared to a sham
procedure” (1). Critics suggested that inadequate
denervation by a ﬁrst-generation device, lack of
operator experience, tightening of the medical ther-
apy, and an unexpectedly great effect of the sham
treatment were likely reasons for the trial ﬁndings
to be negative. However, they could not prevent
the substantial group of believers in the technology
from being shocked. What was left to believe of
the large body of positive reports from the years
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contents of this paper to disclose.As a consequence, large clinical trials aiming to
enroll more than 5,000 patients were canceled, and
engineers went back to the drawing board to discuss
and improve procedural efﬁcacy. In the meantime,
the quest for ﬁnding the “responding” patient con-
tinues, and current datasets are scrutinized with the
aim of ﬁnding potential clues to help optimize patient
selection and ﬁnd potential pleiotropic effects of the
treatment. In particular, the latter resulted in several
interesting observations on speciﬁc endpoints, which
are potentially less variable than blood pressure.Along these lines, in this issue of JACC: Cardiovas-
cular Interventions, Schirmer et al. (2) report on left
atrial (LA) remodeling after renal denervation and
conclude that LA volume index (LAVI) signiﬁcantly
decreases at 6 months post-treatment, irrespective of
blood pressure and heart rate. Additionally, a signif-
icant decrease in premature atrial contractions (PACs)
was observed after treatment, again independent of a
change in LAVI—an interesting observation sup-
porting the body of evidence on the pleiotropic
effects of renal denervation. In particular, system-
atic Holter monitoring in patients pre- and post-
treatment is interesting and illustrates the persis-
tence of this group of investigators in helping us
better understand the potential pleiotropic effects of
this black box procedure. The study adds to several
previous reports demonstrating a potential decrease
in ventricular arrhythmias and renal resistance in-
dex and improvement in arterial stiffness (3–6).
Improvement in these parameters is in line with
what one would expect after an endovascular treat-
ment that signiﬁcantly decreases systemic sympa-
thetic activity (7). More speciﬁcally, they conﬁrm,
in vivo, several animal studies showing the effect
of denervating the kidney on a more pathophysio-
logical level (8).
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study by Schirmer et al. that deserve mentioning.
Left atrial (LA) enlargement has been directly corre-
lated with diastolic dysfunction and increased left
ventricular ﬁlling pressures—a correlation that has
been adopted by international guidelines for assess-
ing diastolic function (9). More speciﬁcally, in these
guidelines, LA volume is one of the parameters
determining diastolic function (10). It remains there-
fore peculiar in the present study by Schirmer et al.
that there is no correlation among change in LAVI,
diastolic function, and blood pressure as well as a lack
of correlation between the change in LA volume and
pro-brain natriuretic peptide levels.
In addition, there seems to be some discrepancy in
the ﬁndings of the present study compared with
previous work coming from the same group. In the
present study, LAVI, as measured using echocardi-
ography, decreases after renal denervation. However,
in previous work, LA volume (measured using mag-
netic resonance imaging) did not appear to change
after renal denervation in the total cohort studied (LA
volume changed from 25.7 cm2 at baseline to 25.3 cm2
at follow-up, p ¼ 0.25) (11). Subsequently, the study
raises again the discussion of whether renal dener-
vation reduces heart rate (12). In the present study,
renal denervation reduced heart rate at 6 months by
at least 8 beats/min. Previous studies showed a
decrease of only 2.1 beats/min at 6 months, and
neither the randomized Symplicity HTN-3 trial nor
the DENER-HTN (Renal Denervation in Hypertension)
trial could conﬁrm a reduction in heart rate in pa-
tients treated with renal denervation compared with
(sham) control groups (1,12,13).
Finally, the authors measured the burden of
PACs in virtually all of their patients at baseline and
6 months and found a signiﬁcant decrease in PACs,
but only in patients with the highest number (upper
tertile) of PACs at baseline.
After summarizing the current body of evidence,
one gets lost. A new technology appears to be safeand effective in reducing blood pressure, and sup-
plementary studies demonstrate that left ventricular
mass regresses, diastolic function improves, LA size
decreases, and the number of PACs decreases mech-
anistically, all in line with what one would expect.
What remains peculiar, however, is that the vast
majority of these pleiotropic effects are only seen in
patients with baseline values in the upper tertile, as
illustrated by the effect on heart rate, PACs, and LA
size. Whether these beneﬁcial ﬁndings are truly due
to a pleiotropic procedural effect or whether regres-
sion to the mean might have had an impact remains a
topic of debate (14). What we are left with today is a
technology that was introduced into practice as a
simple and safe 30-min procedure with the potential
to improve an enormous amount of medical condi-
tions with which the medical community struggled
for many years. Merely 9 years after its market
introduction, the ﬁndings of the ﬁrst decent sham-
controlled, double-blind, randomized, controlled
trial appeared to be negative and put the technology
back in a development stage, a serious setback that not
only resulted in an enormous decrease in the amount
of procedures performed worldwide but, most impor-
tant, decelerated the initiation of larger randomized,
controlled studies—studies that are of paramount
importance to help us to better understand the true
value of this promising new treatment modality.
Because it is highly unlikely that the ﬁndings of a large
number of randomized and observational studies
are all false positive, further research on the topic is
of paramount importance. Fortunately, new sham-
controlled mechanistic studies are currently being
designed to provide us with more insights into the
true potential of the technology and the characteristics
of patients who can beneﬁt from treatment.
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